BSE filing, NSE: WOCKPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Wockhardt Ltd: key numbers
- Share price
- ₹2,050.00
- Market cap
- ₹33,315 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 81.3×Sector 43.8×
- Promoter holding
- 49.32%+0.24% QoQ
- FII holding
- 7.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Other Announcement
Wockhardt's monitoring agency report confirms no deviation in QIP proceeds use for the quarter ended September 30, 2026. It is routine periodic compliance with no financial event.
Wockhardt Management Change
Wockhardt designated Mr. Sumit Garg as Chief Digital & Information Officer, a Senior Management Personnel, from 02 November 2026. He brings over 30 years of technology and transformation leadership experience.
- Execution
- Full-time employment; term not time-bound
Wockhardt Results Update
Wockhardt reported Q2 FY27 PAT of Rs.73 Cr on revenue of Rs.969 Cr, up 24%. Biotech operations grew 68%, driven by emerging markets.
Wockhardt Q2 FY27 Results: Net Profit ₹73 Cr, Down 11.0% YoY
Wockhardt Ltd reported revenue from operations of ₹969 Cr (+23.9% YoY) and net profit of ₹73 Cr (-11.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹73 Cr · -11.0% YoY
Wockhardt Employee Stock Options
Wockhardt allotted 20,000 equity shares at Rs.5 exercise price under its ESOS 2011 scheme. Paid-up capital increases to 16,25,12,169 shares of Rs.5 each.
Wockhardt Board Meeting Date
Wockhardt Ltd intimated that its Board will meet on 2 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-declaration.
Other regulatory approval announcements
All →Sandur Manganese & Iron Ores Regulatory Approval
Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.
- iron ore RoM capacity
- 9.42 MTPA
Neogen Chemicals Regulatory Approval
Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.
Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.